Results 11 to 20 of about 70,518 (282)
PVR—A Prognostic Biomarker Correlated with Immune Cell Infiltration in Hepatocellular Carcinoma
Diagnostics, 2022 The poliovirus receptor (PVR) is a member of the immunoglobulin superfamily (Ig SF) and is essential for the promotion of cancer cell proliferation and invasion. However, the correlation between PVR expression and prognosis as well as immune infiltration
Wen-Feng Liu +5 more
doaj +2 more sources
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
OncoImmunology, 2019 Immune checkpoints are intensively investigated as targets in cancer therapy. T-cell immunoreceptor with immunoglobulin (Ig) and ITIM domains (TIGIT) and its ligand poliovirus receptor (PVR) are recently emerging as novel promising targets in ...
Hauke Stamm +10 more
doaj +2 more sources
The Journal of Clinical Investigation, 2022 Cancer immunotherapy targeting the TIGIT/PVR pathway is currently facing challenges. KIR2DL5, a member of the human killer cell, immunoglobulin-like receptor (KIR) family, has recently been identified as another binding partner for PVR.
Xiaoxin Ren +14 more
doaj +2 more sources
Pvr expression regulators in equilibrium signal control and maintenance of Drosophila blood progenitors. [PDF]
eLife, 2014 Blood progenitors within the lymph gland, a larval organ that supports hematopoiesis in Drosophila melanogaster, are maintained by integrating signals emanating from niche-like cells and those from differentiating blood cells.
Banerjee, Utpal +3 more
core +2 more sources
Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. [PDF]
Scientific Reports, 2017 HIV-specific CD8+ T cells demonstrate an exhausted phenotype associated with increased expression of inhibitory receptors, decreased functional capacity, and a skewed transcriptional profile, which are only partially restored by antiretroviral treatment (
Betts, Michael R +12 more
core +2 more sources
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
Journal for ImmunoTherapy of Cancer, 2022 Recent advances in understanding the roles of immune checkpoints in allowing tumors to circumvent the immune system have led to successful therapeutic strategies that have fundamentally changed oncology practice.
E. Chiang, I. Mellman
semanticscholar +1 more source
Oncogenesis, 2023 Immune-checkpoint (IC) modulators like the poliovirus receptor (PVR) and programmed death ligand 1 (PD-L1) attenuate innate and adaptive immune responses and are potential therapeutic targets for diverse malignancies, including triple-negative breast ...
M. Shrestha +3 more
semanticscholar +1 more source
Frontiers in Immunology, 2022 Background T cell immunoreceptor with Ig and ITIM domains (TIGIT) interacts with poliovirus receptor (PVR) to contribute to cancer immune escape. Recently, TIGIT and PVR have been identified as promising immunotherapy targets.
F. Boissière-Michot +5 more
semanticscholar +1 more source
Journal of experimental & clinical cancer research : CR, 2021 Immune checkpoint molecules, also known as cosignaling molecules, are pivotal cell-surface molecules that control immune cell responses by either promoting (costimulatory molecules) or inhibiting (coinhibitory molecules) a signal.
Baokang Wu +9 more
semanticscholar +1 more source
Biomolecules, 2021 Strategies boosting both innate and adaptive immunity have great application prospects in cancer immunotherapy. Antibodies dual blocking the innate checkpoint CD47 and adaptive checkpoint PD-L1 or TIGIT could achieve durable anti-tumor effects.
Xiuman Zhou +12 more
semanticscholar +1 more source